Thermo Fisher Scientific Inc. announced the grand opening of its East Coast flagship Advanced Therapies Collaboration Center (ATxCC) in Philadelphia, marking the company’s second ATxCC in the United States following the opening of its Carlsbad, California, site.
Together, these centers expand the company’s nationwide network supporting cell and gene therapy (CGT) innovation, providing critical resources to biotech, biopharma and translational researchers developing next-generation cell-based immunotherapies.
“Our new Advanced Therapies Collaboration Center in Philadelphia is designed to help innovators overcome critical hurdles in developing cell and gene therapies,” said Nicole Brockway, president, biosciences, Thermo Fisher Scientific. “This center will play a key role in supporting customers as they progress from the lab to the clinic and, most importantly, bring transformative therapies to patients faster.”
Located within BioLabs for Advanced Therapeutics Philadelphia, a newly expanded 53,000-square-foot biotech incubator in the heart of the city, the Philadelphia ATxCC provides emerging startups and biopharma organizations with direct access to Thermo Fisher’s expert scientists, advanced process development technologies and collaboration opportunities.
For more information about Thermo Fisher’s advanced therapies collaboration center program, please visit https://www.thermofisher.com/celltherapycollaborations.
Read Thermo Fisher's announcement here
